Madrigal Pharma has become the first drugmaker to claim FDA approval for a drug to treat metabolic dysfunction-associated steatohepatitis (MASH), an elusive target that has seen many other ...

The road to the development of treatments for non-alcoholic steatohepatitis (NASH) is littered with failed projects, but US biotech Madrigal Pharma thinks it now has enough evidence for its drug ...

- A father's daring jump across a fractured, 600-foot-high walkway to reach his family during a 7.7-magnitude earthquake in Bangkok captures global attention. - Kwon Young Jun's decision to leap ...